Kolexia
Simand Célestine Oncologie hémato.
Simand Célestine
Oncologie hémato.
Hus Site Icans
Strasbourg, France
71 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Maladie du greffon contre l'hôte Leucémie-lymphome lymphoblastique à précurseurs B et T COVID-19 Aspergillose Maladie aigüe Mycoses

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Bertoli Sarah
Bertoli Sarah
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Dumas Pierre-Yves
Dumas Pierre-Yves
Hôpital Haut-lévêque, Pessac, France
Chevallier Patrice
Chevallier Patrice
Hôpital Hôtel-Dieu Nantes, Nantes, France

Industries

Voir plus
Amgen
4 collaboration(s)
Dernière en 2023
BMS
2 collaboration(s)
Dernière en 2023
Abbvie
2 collaboration(s)
Dernière en 2022
Pfizer
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Transient red blood cell agglutination after Magrolimab administration in acute myeloid leukemia.
International journal of laboratory hematology   17 février 2024
OGILAR: Open-label, Phase 2 Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Essai Clinique (French Innovative Leukemia Organisation)   05 février 2024
Bone marrow graft versus peripheral blood graft in haploidentical hematopoietic stem cells transplantation: a retrospective analysis in1344 patients of SFGM-TC registry.
Journal of hematology & oncology   07 janvier 2024
Real-World Outcomes Using Front-Line Midostaurine in Combination with Intensive Chemotherapy for Patients Aged ≥ 60 Years Old with FLT3 Mutated Acute Myeloid Leukemia
65th ASH Annual Meeting Abstracts   02 novembre 2023
Efficacy and Tolerance of Brexucabtagene Autoleucel in Adults with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia : A Graall Study from the Descar-T Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Current Results of Intensive Therapy in Younger Adults with Acute Myeloid Leukemia (AML): The Large Randomized French Backbone Intergroup (BIG)-1 Study on Behalf of the Filo, ALFA, and SFGM-TC Study Groups
65th ASH Annual Meeting Abstracts   02 novembre 2023
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
65th ASH Annual Meeting Abstracts   02 novembre 2023
Early Autologous Hematopoietic Stem Cells (AHSC) Boost (HCB) to Overcome Immune Effector Cell-Associated Hematotoxicity (ICAHT) after CAR T-Cell Therapy for Lymphoma: A Single Center Experience
65th ASH Annual Meeting Abstracts   02 novembre 2023
Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. a Filo Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Cancer medicine   08 décembre 2022